Der DAX® gab im Tagesverlauf rund ein Prozent nach. Nach dem Sprint in der zweiten Wochenhälfte, muss erst einmal durchgeatmet werden. Zudem ist die Nachrichtenlage heute recht mau. Es gibt also
News
The Big 3’s Potential Chinese Alliance – Surviving In The EV Industry
In his podcast addressing the markets today, Louis Navellier offered the following commentary.
If you wish to listen to this commentary, please click here.
Relief Rally
We have a pretty good
Logica Capital August 2023 Commentary
Logica Capital commentary for the month ended August 31, 2023.
Summary
Equity markets stumbled a tad in August, and VIX/Implied Volatility didn’t respond, as demonstrated by the concurrent negative
Logica Capital August 2023 Commentary
Logica Capital commentary for the month ended August 31, 2023.
Summary
Equity markets stumbled a tad in August, and VIX/Implied Volatility didn’t respond, as demonstrated by the concurrent negative
S&P 500 Dead Cat Bounce – Smelling FOMC Outcome
S&P 500 made a dead cat bounce mixed with an intraday short squeeze, and given likely rise in yields (10y back above 4.33%) and muted HYG, I favor a slow decline to prevail today. Not that FOMC
Ocado Retail – Consumers Show Resilience
- Q3 revenue up 7.2% to £569.6m as prices rise 8.4%
- Volumes returned to positive territory in final month of the quarter
- Average orders per week and active customers grow 1.9% and 1.5%
- No
Tagesausblick für 20.09.: DAX vor Fed-Entscheidung leichter. Auto- und Immobilienaktien im Blickpunkt.
Der DAX® schloss mit leichten Verlusten. Aus den USA kamen keinerlei Impulse und aus Deutschland kamen zunächst keine guten Meldungen. So lag der Auftragsbestand in der deutschen Industrie im Juli
NVIDIA Triples In Value Since The Start Of 2023, Leading The Top 10 Most Popular Stocks
- A £1000 investment in NVIDIA Corp (NASDAQ:NVDA) at the start of 2023 would have returned an impressive £3,067 on 15 September 2023.
- The 10 most popular stocks returned an average of 68.6% since
NVIDIA Triples In Value Since The Start Of 2023, Leading The Top 10 Most Popular Stocks
- A £1000 investment in NVIDIA Corp (NASDAQ:NVDA) at the start of 2023 would have returned an impressive £3,067 on 15 September 2023.
- The 10 most popular stocks returned an average of 68.6% since
NVIDIA Triples In Value Since The Start Of 2023, Leading The Top 10 Most Popular Stocks
- A £1000 investment in NVIDIA Corp (NASDAQ:NVDA) at the start of 2023 would have returned an impressive £3,067 on 15 September 2023.
- The 10 most popular stocks returned an average of 68.6% since
BioNTech – Neuer Coronaimpfstoff wirkt noch nicht
Zahlreichen Meldungen zufolge sind die beiden Minister Christian Lindner und Boris Pistorius positiv auf Corona getestet worden. Bundesgesundheitsminister Karl Lauterbach hat sich gestern eine
Die meistgehandelten Produkte: Anleger tendenziell bullish
Der DAX stagniert weiterhin. Anleger warten auf die morgige Leitzinsentscheidung der FED. Die gemischten Zukunftserwartungen der Anleger lassen sich an dem stagnierenden Kurs des deutschen
3 Reasons Price Weakness Is a Buying Opportunity For Lennar
Key Points
- Lennar continues to outpace consensus on strength in deliveries.
- Signs of normalization are mounting and a return to growth is at hand.
- Solid cash flow allows debt reduction
Name A Better Trio Than These Underrated High Potential Stocks
Key Points
- It is tough to find the perfect growth ecosystem; much more, be able to invest in it without jumping through hoops.
- These three stocks could expose a portfolio of high growth
Retirement Planning for Business Owners: 10 Strategies to Boost Your Savings
Owning and managing a business is a monumental responsibility. As a business owner, you make all of the decisions for your business, which affects your income and the livelihoods of your employees.
A Black and White Approach To Retirement: Advisors Weigh In on BlackRock’s Unconventional Recommendation
It might be time to abandon the idea of a balanced portfolio.
Traditional wisdom holds that investors should diversify their assets. While working and saving, you should invest in a mix of assets
The Fed Should Not Increase Key Interest Rates Further
In his podcast addressing the markets today, Louis Navellier offered the following commentary.
No Interest Rate Hike
The Federal Open Market Committee (FOMC) statement on Wednesday will
The Fed Should Not Increase Key Interest Rates Further
In his podcast addressing the markets today, Louis Navellier offered the following commentary.
No Interest Rate Hike
The Federal Open Market Committee (FOMC) statement on Wednesday will
OceanaGold Begins Trading on the OTCQX
Blank Document Template
(VANCOUVER) OceanaGold Corporation (TSX: OGC) (“OceanaGold” or the “Company”) - https://www.commodity-tv.com/ondemand/companies/profil/oceanagold-corp/ - is pleased
OceanaGold nimmt den Handel an der OTCQX auf
Blank Document Template
(VANCOUVER) OceanaGold Corporation (TSX: OGC) ("OceanaGold" oder das "Unternehmen") - https://www.commodity-tv.com/ondemand/companies/profil/oceanagold-corp/ - freut
MAG Silver veröffentlicht zweiten jährlichen Nachhaltigkeitsbericht
Vancouver, B.C. MAG Silver Corp. (TSX / NYSE American: MAG) ("MAG", "MAG Silver" oder das "Unternehmen") - https://www.commodity-tv.com/ondemand/companies/profil/mag-silver-corp/ - freut
MAG Silver Publishes Second Annual Sustainability Report
Vancouver, B.C. MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG”, “MAG Silver”, or the “Company”) - https://www.commodity-tv.com/ondemand/companies/profil/mag-silver-corp/ - is pleased to
Die meistgehandelten Produkte: DAX-Bären decken sich ein
Zum Start in die Woche scheinen die Bären beim DAX® das Zepter in der Hand zu halten. Deutlich wird dies durch den fallenden Kurses des DAX® seit Börsenöffnung, aber auch durch die meist gehandelten
BioNTech und CEPI geben Partnerschaft zur Entwicklung eines mRNA-Mpox-Impfstoffs und zur Unterstützung von CEPIs 100-Tage-Ziel bekannt
- BioNTech bereitet klinische Phase-1/2-Studie für das mRNA-basierte Mpox-Impfstoffprogramm BNT166 vor
- Die Coalition for Epidemic Preparedness Innovations (CEPI) stellt bis zu 90 Millionen US-Dollar
BioNTech und CEPI geben Partnerschaft zur Entwicklung eines mRNA-Mpox-Impfstoffs und zur Unterstützung von CEPIs 100-Tage-Ziel bekannt
- BioNTech bereitet klinische Phase-1/2-Studie für das mRNA-basierte Mpox-Impfstoffprogramm BNT166 vor
- Die Coalition for Epidemic Preparedness Innovations (CEPI) stellt bis zu 90 Millionen US-Dollar